Low dose nivolumab in metastatic mucosal melanoma: a case report
GACETA MEXICANA DE ONCOLOGIA(2023)
摘要
We present the case of a 77-year-old man with metastatic mucosal melanoma, unable to afford standard doses of immunotherapy, who was treated with nivolumab at a lower dose of 0.5 mg/kg every 2 weeks. Drug activity was demonstrated through both objective tumor response and an immune-related adverse event. This suggests that a lower dose of nivolumab could be a viable alternative for patients with advanced mucosal melanoma at a high risk of treatment-related financial toxicity. Further research is needed to evaluate the efficacy of lower doses of immunotherapy, including its impact on long term outcomes.
更多查看译文
关键词
metastatic mucosal melanoma,nivolumab
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要